GlassScriptPhysician profile
Bethany Bondy
NPI 1619390309
$2,653.12
in general payments reported to CMS, 2019-2025
25 companies · $390 in 2025
The $390 reported for 2025 was more than what 81% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $570 · 2022: $535 · 2023: $618 · 2024: $539 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $371.04 | 2023-2025 | Myfembree, Gemtesa |
| Avion Pharmaceuticals | $369.43 | 2021-2023 | Balcoltra |
| Astellas Pharma US INC | $268.83 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $262.43 | 2021-2024 | |
| Sage Therapeutics, LLC | $183.94 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $150.83 | 2022-2025 | Aptima, Thinprep 2000 Processor, Fluent Fluid Management System |
| Organon LLC | $135.95 | 2022-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $120.26 | 2023-2024 | |
| Myovant Sciences INC. | $120.23 | 2021-2022 | |
| Agile Therapeutics, INC. | $112.19 | 2021-2023 | Twirla |
| Evofem Biosciences, INC. | $84.39 | 2021-2022 | |
| Aspira Women'S Health INC | $75.00 | 2021 | |
| Merck Sharp & Dohme LLC | $59.18 | 2021-2024 | Gardasil, Gardasil 9 |
| Exeltis, USA INC. | $54.11 | 2021-2025 | Slynd |
| Coopersurgical, INC. | $51.92 | 2022-2025 | Paragard T 380a |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $41.36 | 2022-2024 | |
| Millicent US INC | $35.54 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $34.24 | 2021 | |
| Mylan Pharmaceuticals INC. | $23.90 | 2021-2022 | |
| Therapeuticsmd, INC. | $22.52 | 2022 | |
| Dexcom, INC. | $18.55 | 2024 | Dexcom G6 Transmitter |
| Teleflex LLC | $15.89 | 2025 | Quikclot |
| Solventum Corporation | $14.62 | 2024 | Prevena, V.A.C.Ulta |
| Daiichi Sankyo INC. | $13.59 | 2021 | |
| Lupin INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Bondy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.